You can buy or sell SELB and other stocks, options, ETFs, and crypto commission-free!
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. Read More The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
52 Week High
52 Week Low
Research And Development
Seeking AlphaMay 14
Selecta Biosciences, Inc. CEO Carsten Brunn on Q1 2019 Results - Earnings Call Transcript
Selecta Biosciences, Inc. (NASDAQ:SELB) Q1 2019 Results Conference Call May 9, 2019 8:30 AM ET Company Participants Elona Kogan - General Counsel & Corporate Secretary Carsten Brunn - CEO Stephen Smolinski - CCO Conference Call Participants Difei Yang - Mizuho Securities Derek Archila - Stifel Operator Thank you for holding. Welcome to the Selecta Biosciences First Quarter Financial Results Conference Call. [Operator Instructions] This call is being webcast live on the Investors and Media section o...
Associated PressMay 2
Selecta Biosciences to Announce Date of First Quarter 2019 Financial Results Conference Call
WATERTOWN, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced that it plans to issue its first quarter 2019 financial results before the open of the U.S. financial markets on Thursday, May 09, 2019. At 8:30 a.m. ET that day, Selecta will host a conference call and live audio ...
-$0.35 per share
-$0.31 per share